Werner Verbiest

Biography

 Werner Verbiest is Global Head of Janssen Diagnostics, which was formed from the legacy organizations Virco (Infectious Diseases), Veridex (Oncology) and the Johnson & Johnson Companion Diagnostics Center of Excellence. Janssen Diagnostics focuses on personalized medicine within Janssen, incorporating therapeutic, diagnostic and real world data/health information technology solutions to improve patient outcomes. Werner joined the Johnson & Johnson Family of Companies in 2002 following the acquisition of Tibotec-Virco. Before joining, he was active since 1992 in HIV drug development and hepatitis B therapeutic vaccine development in the International Clinical Research & Development group of the Janssen Research Foundation.  He was one of the first employees of Virco in 1997 and had an instrumental role in Virco’s growth as Project and Business Development Director (1998), Managing Director (Virco Ireland, Ltd, 1999), Vice President of New Products Marketing and Pharma Business (2001) and General Manager from 2004 until its integration into Janssen Diagnostics. Werner has been continually active in all phases of HIV clinical trial strategy and implementation, biomarker development (collaborative surrogate marker validation working groups with the United States Food andl Drug Administration and the European Medicines Agency), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine. In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach both within and outside of Johnson & Johnson, including several board seats in different precision medicine and diagnostic organizations, including the European Personalised Medicine Association (EPEMED) and AdvaMedDx.

Research Interest

 .....